Samuel Leung

25.6k total citations · 10 hit papers
121 papers, 15.5k citations indexed

About

Samuel Leung is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Samuel Leung has authored 121 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 43 papers in Cancer Research and 32 papers in Molecular Biology. Recurrent topics in Samuel Leung's work include Endometrial and Cervical Cancer Treatments (31 papers), Breast Cancer Treatment Studies (31 papers) and HER2/EGFR in Cancer Research (25 papers). Samuel Leung is often cited by papers focused on Endometrial and Cervical Cancer Treatments (31 papers), Breast Cancer Treatment Studies (31 papers) and HER2/EGFR in Cancer Research (25 papers). Samuel Leung collaborates with scholars based in Canada, United States and United Kingdom. Samuel Leung's co-authors include Torsten O. Nielsen, Maggie C.U. Cheang, Charles M. Perou, David Voduc, Matthew J. Ellis, Philip S. Bernard, Joel S. Parker, Sherri R. Davies, Dongxia Gao and Stephen Chia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Samuel Leung

120 papers receiving 15.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Maggie C.U. Cheang et al. profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. profile →
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

2008 945 citations Maggie C.U. Cheang, Samuel Leung et al. Clinical Cancer Research profile →
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer

2017 631 citations Aline Talhouk, Melissa K. McConechy et al. profile →
A clinically applicable molecular-based classification for endometrial cancers

2015 622 citations Aline Talhouk, Melissa K. McConechy et al. profile →
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

2008 618 citations Martin Köbel, Samuel Leung et al. profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival

2011 539 citations Samuel Leung, Torsten O. Nielsen et al. profile →
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series

2018 490 citations Stefan Kommoss, Melissa K. McConechy et al. profile →
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer

2015 437 citations Dongxia Gao, Samuel Leung et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Leung Canada	49	7.0k	6.7k	5.3k	2.7k	2.3k	121	15.5k
Britta Weigelt United States	70	8.4k 1.2×	8.1k 1.2×	7.8k 1.5×	1.6k 0.6×	1.5k 0.6×	311	19.1k
Russell R. Broaddus United States	69	4.4k 0.6×	4.9k 0.7×	5.8k 1.1×	3.6k 1.3×	3.4k 1.5×	286	15.1k
James D. Brenton United Kingdom	47	6.2k 0.9×	4.0k 0.6×	5.9k 1.1×	632 0.2×	1.8k 0.8×	167	12.5k
Douglas A. Levine United States	70	6.3k 0.9×	6.7k 1.0×	9.3k 1.8×	4.5k 1.7×	7.3k 3.2×	256	22.4k
David G. Huntsman Canada	86	5.6k 0.8×	6.8k 1.0×	10.9k 2.1×	4.9k 1.8×	7.1k 3.0×	350	24.7k
Lars A. Akslen Norway	67	11.6k 1.7×	14.0k 2.1×	13.8k 2.6×	1.4k 0.5×	1.1k 0.5×	314	29.1k
Bryan T. Hennessy Ireland	59	6.4k 0.9×	9.0k 1.4×	9.7k 1.8×	400 0.1×	1.5k 0.7×	266	19.8k
Martin Köbel Canada	54	2.1k 0.3×	2.5k 0.4×	3.1k 0.6×	3.6k 1.3×	5.1k 2.2×	198	10.1k
Panagiotis A. Konstantinopoulos United States	52	1.9k 0.3×	5.8k 0.9×	5.6k 1.1×	701 0.3×	2.2k 0.9×	209	10.6k
Sarina A. Piha‐Paul United States	53	3.1k 0.5×	9.3k 1.4×	4.0k 0.8×	597 0.2×	627 0.3×	432	14.7k

Countries citing papers authored by Samuel Leung

Since Specialization

Citations

This map shows the geographic impact of Samuel Leung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Leung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Leung more than expected).

Fields of papers citing papers by Samuel Leung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Leung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Leung. The network helps show where Samuel Leung may publish in the future.

Co-authorship network of co-authors of Samuel Leung

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Leung. A scholar is included among the top collaborators of Samuel Leung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Leung. Samuel Leung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Almadani, Noorah, Rebecca Ho, F. Kommoss, et al.. (2025). Prognostic values of molecular subtypes and SWI/SNF protein expression in de‐differentiated/undifferentiated endometrial carcinoma. Histopathology. 86(7). 1053–1063. 1 indexed citations

Farahani, Hossein, Maryam Asadi, Matthew O. Wiens, et al.. (2024). AI-based histopathology image analysis reveals a distinct subset of endometrial cancers. Nature Communications. 15(1). 4973–4973. 13 indexed citations

Jamieson, Amy, Marcel Grube, Samuel Leung, et al.. (2024). Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion. International Journal of Gynecological Cancer. 34(4). 544–549. 5 indexed citations

Nielsen, Torsten O., Samuel Leung, Nazia Riaz, et al.. (2023). Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial. Histopathology. 83(6). 903–911. 3 indexed citations

Huvila, Jutta, Emily F. Thompson, Amy Lum, et al.. (2023). Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype. Histopathology. 83(6). 880–890. 17 indexed citations

Stovgaard, Elisabeth Specht, Maj‐Britt Jensen, Karama Asleh, et al.. (2022). Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers. 14(15). 3808–3808. 2 indexed citations

Almadani, Noorah, Jennifer Pors, Samuel Leung, et al.. (2021). International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings. International Journal of Gynecological Pathology. 40(6). 533–540. 13 indexed citations

Patch, Ann‐Marie, Cameron Snell, Deborah S. Smith, et al.. (2020). FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. Clinical Cancer Research. 26(17). 4569–4580. 14 indexed citations

Tessier‐Cloutier, Basile, Jennifer Pors, Emily F. Thompson, et al.. (2020). Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. Modern Pathology. 34(2). 508–518. 46 indexed citations

10.

Talhouk, Aline, Heather Derocher, Samuel Leung, et al.. (2019). Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research. 25(8). 2537–2548. 108 indexed citations

11.

Britton, Heidi, Leo Huang, Amy Lum, et al.. (2019). Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecologic Oncology. 153(3). 487–495. 89 indexed citations

12.

Ricciardelli, Carmela, Tina Bianco‐Miotto, Shalini Jindal, et al.. (2018). The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research. 24(10). 2328–2341. 62 indexed citations

13.

McConechy, Melissa K., Aline Talhouk, Samuel Leung, et al.. (2016). Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Clinical Cancer Research. 22(12). 2865–2873. 144 indexed citations

14.

Talhouk, Aline, Lien Hoang, Melissa K. McConechy, et al.. (2016). Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecologic Oncology. 143(1). 46–53. 154 indexed citations

15.

Nguyen, Minh, Shuichi Miyakawa, Junichi Kato, et al.. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research. 21(24). 5552–5562. 19 indexed citations

16.

Kharma, Budiman, Tsukasa Baba, Noriomi Matsumura, et al.. (2014). STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer. Cancer Research. 74(22). 6519–6530. 62 indexed citations

17.

Chia, Stephen, Vivien Bramwell, Dongsheng Tu, et al.. (2012). A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18(16). 4465–4472. 220 indexed citations

18.

Cheang, Maggie C.U., K. David Voduc, Dongsheng Tu, et al.. (2012). Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18(8). 2402–2412. 105 indexed citations

19.

Nielsen, Torsten O., Joel S. Parker, Samuel Leung, et al.. (2010). A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 16(21). 5222–5232. 542 indexed citations breakdown →

20.

Joshi, Bharat, Scott S. Strugnell, Jacky G. Goetz, et al.. (2008). Phosphorylated Caveolin-1 Regulates Rho/ROCK-Dependent Focal Adhesion Dynamics and Tumor Cell Migration and Invasion. Cancer Research. 68(20). 8210–8220. 218 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact